UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab

Clinical cancer research, 2019-07, Vol.25 (13), p.3839-3846

2019

Volltextzugriff (PDF)

The Emerging Role of c-Met in Carcinogenesis and Clinical Implications as a Possible Therapeutic Target

Journal of oncology, 2022-01, Vol.2022, p.5179182-12

2022

Volltextzugriff (PDF)

Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program

Journal for immunotherapy of cancer, 2019-04, Vol.7 (1), p.99-99, Article 99

2019

Volltextzugriff (PDF)

Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study

Journal of clinical oncology, 2010-04, Vol.28 (10), p.1645-1651

2010

Volltextzugriff (PDF)

Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin as First-Line Chemotherapy in Advanced Transitional Cell Carcinoma of the Urothelium: Results of a Randomized Phase 2 Trial

European urology, 2007-07, Vol.52 (1), p.134-141

2007

Volltextzugriff (PDF)

Recent developments in second and third line therapy of metastatic renal cell carcinoma

Expert review of anticancer therapy, 2016-05, Vol.16 (5), p.469-471

2016

Volltextzugriff (PDF)

Targeted Therapy in the Treatment of Metastatic Renal Cell Cancer

Oncology, 2009-01, Vol.77 (Suppl 1), p.122-131

2009

Volltextzugriff (PDF)

Clinical management of metastatic kidney cancer: the role of new molecular drugs

Future Oncology, 2016-01, Vol.12 (1), p.83-93

2016

Volltextzugriff (PDF)

Incidental finding of non-Hodgkin's lymphoma in a patient affected by castration-sensitive prostate cancer: A case report

Medicine (Baltimore), 2019-03, Vol.98 (11), p.e14805

2019

Volltextzugriff (PDF)

Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program

Lung cancer (Amsterdam, Netherlands), 2020-02, Vol.140, p.59-64

2020

Volltextzugriff (PDF)

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy

The New England journal of medicine, 2016-12, Vol.375 (23), p.2246-2254

2016

Volltextzugriff (PDF)

Occurrence of second primary malignancies in patients with neuroendocrine tumors of the digestive tract: A case report

Medicine (Baltimore), 2019-07, Vol.98 (29), p.e16508

2019

Volltextzugriff (PDF)

ZeOxaNMulti Trial: A Randomized, Double-Blinded, Placebo-Controlled Trial of Oral PMA-zeolite to prevent Chemotherapy-Induced Side Effects, in particular, Peripheral Neuropathy

Molecules (Basel, Switzerland), 2020-05, Vol.25 (10), p.2297

2020

Volltextzugriff (PDF)

An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the ‘Pamerit’ study

Japanese journal of clinical oncology, 2021-03, Vol.51 (3), p.484-491

2021

Volltextzugriff (PDF)

We need both randomized trials and real-world data: the example of everolimus as second-line therapy for mRCC

Future oncology (London, England), 2014-10, Vol.10 (12), p.1893-1896

2014

Volltextzugriff (PDF)

Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study

Journal of cancer research and clinical oncology, 2017-05, Vol.143 (5), p.783-791

2017

Volltextzugriff (PDF)

Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results

European urology, 2018-01, Vol.73 (1), p.62-68

2018

Volltextzugriff (PDF)

Phase II Study of Sorafenib in Patients With Sunitinib-Refractory Metastatic Renal Cell Cancer

Journal of clinical oncology, 2009-09, Vol.27 (27), p.4469-4474

2009

Volltextzugriff (PDF)

Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort

European journal of cancer (1990), 2013-06, Vol.49 (9), p.2134-2142

2013

Volltextzugriff (PDF)

Second-line treatment in renal cell carcinoma: clinical experience and decision making

Therapeutic Advances in Urology, 2021, Vol.13, p.17562872211022870-17562872211022870

2021

Volltextzugriff (PDF)

Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population

Clinical genitourinary cancer, 2019-08, Vol.17 (4), p.291-298

2019

Volltextzugriff (PDF)

Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Dell’Italia Meridionale

Journal of clinical oncology, 2005-08, Vol.23 (22), p.4866-4875

2005

Volltextzugriff (PDF)

Renal cell carcinoma in adult patients with thalassaemia major: a description of three cases

British journal of haematology, 2014-06, Vol.165 (6), p.887-888

2014

Volltextzugriff (PDF)

1 – 25 von 142

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(133)
Mit Volltextzugriff
(124)

Publikationsform

Sprache

Englisch
(142)
Italienisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(98)
Life Sciences & Biomedicine
(96)
Humans
(72)
Oncology
(72)
Male
(53)
Female
(49)
Middle Aged
(49)
Aged
(48)
Adult
(35)
Treatment Outcome
(27)
Tumors
(23)
Antineoplastic Agents - Therapeutic Use
(21)
Carcinoma, Renal Cell - Drug Therapy
(21)
Chemotherapy
(21)
Renal Cell Carcinoma
(21)
Biological And Medical Sciences
(20)
Medical Sciences
(20)
Kidney Neoplasms - Drug Therapy
(19)
Metastasis
(19)
Disease-Free Survival
(18)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab

The Emerging Role of c-Met in Carcinogenesis and Clinical Implications as a Possible Therapeutic Target

The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?

Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program

Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study

Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin as First-Line Chemotherapy in Advanced Transitional Cell Carcinoma of the Urothelium: Results of a Randomized Phase 2 Trial

Recent developments in second and third line therapy of metastatic renal cell carcinoma

Targeted Therapy in the Treatment of Metastatic Renal Cell Cancer

Clinical management of metastatic kidney cancer: the role of new molecular drugs

Incidental finding of non-Hodgkin's lymphoma in a patient affected by castration-sensitive prostate cancer: A case report

Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy

Occurrence of second primary malignancies in patients with neuroendocrine tumors of the digestive tract: A case report

ZeOxaNMulti Trial: A Randomized, Double-Blinded, Placebo-Controlled Trial of Oral PMA-zeolite to prevent Chemotherapy-Induced Side Effects, in particular, Peripheral Neuropathy

An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the ‘Pamerit’ study

We need both randomized trials and real-world data: the example of everolimus as second-line therapy for mRCC

Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study

Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results

Phase II Study of Sorafenib in Patients With Sunitinib-Refractory Metastatic Renal Cell Cancer

Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort

Second-line treatment in renal cell carcinoma: clinical experience and decision making

Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population

Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Dell’Italia Meridionale

Renal cell carcinoma in adult patients with thalassaemia major: a description of three cases

Prevalence of malnutrition in patients at first medical oncology visit: the PreMiO study

Suchergebnisse filtern